Pembrolizumab Plus Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
European Urology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study
Eur Urol 2022 Aug 30;[EPub Ahead of Print], EY Yu, JM Piulats, G Gravis, PCC Fong, T Todenhöfer, B Laguerre, JA Arranz, S Oudard, C Massard, J Heinzelbecker, LT Nordquist, J Carles, MP Kolinsky, M Augustin, H Gurney, A Tafreshi, XT Li, P Qiu, CH Poehlein, C Schloss, JS de BonoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.